Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Evaxion Biotech A/S - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
EVAX
Nasdaq
2830
www.evaxion-biotech.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Evaxion Biotech A/S
Evaxion Biotech price target lowered to $6 from $35 at Lake Street
- Feb 5th, 2025 1:45 pm
EVAX Ups Cash to Further Research
- Feb 5th, 2025 11:06 am
Evaxion announces closing of $10.8 million public offering
- Jan 31st, 2025 9:05 pm
Evaxion announces pricing of $10.8 million public offering
- Jan 30th, 2025 1:00 pm
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
- Jan 28th, 2025 1:15 pm
Evaxion concludes subject dosing in Phase II trial of melanoma vaccine
- Jan 16th, 2025 11:08 am
Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01
- Jan 15th, 2025 1:00 pm
EVAX Adjusts Share Ratio
- Jan 15th, 2025 10:13 am
Evaxion announces completion of ADS ratio change
- Jan 14th, 2025 9:05 pm
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
- Jan 10th, 2025 1:00 pm
Evaxion announces plan to implement ADS ratio change
- Dec 30th, 2024 1:00 pm
Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity
- Dec 17th, 2024 1:00 pm
Evaxion establishes new AI-derived precision cancer vaccine concept
- Dec 12th, 2024 1:00 pm
Evaxion announces 2025 milestones reflecting continued strong strategy execution
- Dec 9th, 2024 1:00 pm
Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress
- Dec 2nd, 2024 1:00 pm
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
- Nov 13th, 2024 1:00 pm
EVAX Racks up Positive Test Results
- Nov 12th, 2024 2:00 pm
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
- Nov 12th, 2024 1:00 pm
Evaxion announces business update and third quarter 2024 financial results
- Oct 31st, 2024 12:00 pm
EVAX Exceeds Estimates and Confirms Partnership
- Oct 31st, 2024 10:19 am
Scroll